Investor Presentation

51 Investor presentation First six months of 2022 Icodec Glargine U100 Change Icodec 9 * * in HbA1c 8 7 6 M 0.0 Icodec, a once-weekly insulin, improved PPG control, HbA1c, and increased the number of patients reaching target in a phase 2 trial Icodec showed statistically significant post prandial blood glucose control FPG (mmol/L) Numerical improvement in HbA1c The proportion of patients on Icodec reaching HbA1c targets was higher Icodec Glargine U100 Novo NordiskⓇ over 26 weeks Glargine U100 Proportion of patients 100% -0.2 -0.4 -0.6 -0.8 -1.0 5 Breakfast +90 min Lunch +90 min Evening meal -1.2 +90 min Bedtime 04:00 Breakfast next day -1.4 50% -1.15 25% -1.33 72% 75% 68% 49% 39% -1.6 0% 048 12 16 20 26 < 7.0% Weeks ≤ 6.5% HbA1c target *Statistically significant at week 26 PPG: Post-prandial control; FPG: Fasting plasma glucose

View entire presentation